Family

+

−

• No Family data available.

• 15 United States
• 10 France
• 8 Japan
• 7 China
• 5 Korea
• 2 Other

Patent Owner(s)

Patent Owner	Address
WISCONSIN ALUMNI RESEARCH FOUNDATION	614 WALNUT STREET MADISON WI 53726

International Classification(s)

• A61K:PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOS....
• C07K:PEPTIDES

Inventor(s)

Inventor Name	Address	# of filed Patents	Total Citations
Brown, Kyle Alexander	Queens, US	1	0
# of filed Patents : 1 Total Citations : 0
Gellman, Samuel Helmer	Madison, US	17	60
# of filed Patents : 17 Total Citations : 60
Morris, Rylie Kathleen	Madison, US	1	0
# of filed Patents : 1 Total Citations : 0

Cited Art Landscape

Load Citation

• No Cited Art to Display

Loading Cited Art Landscape...

Patent Citation Ranking

• 0 Citation Count
• A61K Class

• 0 % this patent is cited more than
• < 1 Age

Forward Cite Landscape

Load Citation

• No Forward Cites to Display

Loading Forward Cite Landscape...

Maintenance Fees

Fee	Large entity fee	small entity fee	micro entity fee	due date
3.5 Year Payment	$1600.00	$800.00	$400.00	Jul 23, 2028
7.5 Year Payment	$3600.00	$1800.00	$900.00	Jul 23, 2032
11.5 Year Payment	$7400.00	$3700.00	$1850.00	Jul 23, 2036

Fee	Large entity fee	small entity fee	micro entity fee
Surcharge - 3.5 year - Late payment within 6 months	$160.00	$80.00	$40.00
Surcharge - 7.5 year - Late payment within 6 months	$160.00	$80.00	$40.00
Surcharge - 11.5 year - Late payment within 6 months	$160.00	$80.00	$40.00
Surcharge after expiration - Late payment is unavoidable	$700.00	$350.00	$175.00
Surcharge after expiration - Late payment is unintentional	$1,640.00	$820.00	$410.00

Full Text

US Patent Application No: 2025/0026,782

ACTIVATING APPENDAGES TO INDUCE POLYPHARMACOLOGY IN PEPTIDE HORMONE ANALOGUES, INCLUDING DUAL GLP-1R / GIP AGONISM

---

Abstract

---

Compounds, method of making the compounds, and methods of using the compounds to treat Type 2 diabetes and obesity in mammals, including humans. The compounds are dual GLP-1 receptor and GIP receptor agonists in which at least one side chain of a residue in GLP-1 and/or GIP is modified such that the modified GLP-1 and GIP are agonists of both GLP-1 receptor and GIP receptor.

---

 

---

Description

---

Claims

---

Claims data not available

---

Legal Events

• No Legal Status data available.